Скачать или смотреть Omicron Infections & CMV drugs │ GOLD Weekly News Roundup

In our weekly news roundup, we look at three of the top stories from around the world this week:

1. On Monday, the Scientific Advisory Group for Emergencies met to discuss the emerging Omicron variant. Scientists concluded that booster jabs will help, but “any significant reduction in protection against infection could still result in a very large wave of infections.”

2. The FDA have voted to recommend approval for the emergency use of molnupiravir, an oral antiviral produced by Merck & Co and Ridgeback Biotherapeutics to be taken after COVID-19 symptom onset.

3. Takeda's post-transplant cytomegalovirus (CMV) drug, Livtencity, has gained FDA approval. The drug will be available to patients of 12 years or older with post-transplant CMV that is resistant to existing drugs.

#toldbyGOLD #news #COVID19 #boosterjabs #FDA